Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Peter Merrill

Podiatrist, Foot & Ankle Surgery Tucson, AZ Doctor of Podiatric Medicine

NPI 1699099978 CMS profile 76953

2163 W Orange Grove Rd, Tucson, AZ 85741

Open in the dashboard

General payments

$7,410

88 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Peter Merrill of Tucson, AZ is reported in the CMS Open Payments database as having received $7,410 across 88 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,290 16
2024 General $4,770 14
2023 General $632 12
2022 General $225 12
2021 General $115 6
2020 General $87 7
2019 General $290 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Peter Merrill
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Peter Merrill were reported at $1,290. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Peter Merrill Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $290 $389 $118–$1,406 $163
2020 $87 $191 $62–$691 $114
2021 $115 $329 $104–$1,341 $132
2022 $225 $419 $125–$1,611 $149
2023 $632 $377 $128–$1,164 $160
2024 $4,770 $394 $134–$1,168 $164
2025 $1,290 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fusion Orthopedics USA, LLC $5,347 5 payments
  2. Fusion Orthopedics, LLC. $572 2 payments
  3. Orthofix Medical, Inc. $183 14 payments
  4. Smith+Nephew, Inc. $148 8 payments
  5. Treace Medical Concepts, Inc. $108 4 payments
  6. Stryker Corporation $94 2 payments
  7. GRT US Holding, Inc. $77 3 payments
  8. AbbVie, Inc. $77 4 payments
  9. DePuy Synthes Sales Inc. $70 2 payments
  10. Averitas Pharma Inc. $68 4 payments
  11. Other $666 40 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $3,191 5 payments
  2. Consulting Fee $1,800 1 payment
  3. Food and Beverage $1,491 81 payments
  4. Travel and Lodging $928 1 payment
Products named General payments · program years 2019–2025
  1. LapiLock Foot And Ankle $2,224 4 payments
  2. LapiLock Orthopedic $967 1 payment
  3. Physio-Stim $151 7 payments
  4. Qutenza $145 7 payments
  5. LAPIPLASTY SYSTEM $94 3 payments
  6. Physio-Stim Osteogenesis Stimulator $83 9 payments
  7. DALVANCE $77 4 payments
  8. VA-LCP PLATES & SCREWS $70 2 payments
  9. BME NITINOL CONTINUOUS COMPRESSION IMPLANTS $70 2 payments
  10. KRYSTEXXA $62 4 payments
  11. Other $1,064 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

99

Median for Podiatry: 160

Drug cost

$1,022

Median for Podiatry: $2,368

Branded share of claims

12.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Terbinafine Hcl Generic 29 $351
Cephalexin Generic 25 $320
Methylprednisolone Generic 33 $231
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $119

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$350,190

Of which drugs: $190,179

Medicare patients

894

Average age 77

Services billed

7,569

511 women, 383 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 50%
Diabetes 33%
Chronic kidney disease 26%
Ischemic heart disease 25%
Depression 22%
Atrial fibrillation 21%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 102 164 $853
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 45 152 $98
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 141 474 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DALVANCE
  • AbbVie, Inc. $19
$19 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

88 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record